Minimally Invasive Nonopioid Pain Management Will Expand With PNS
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 4 Analysts
Published
30 May 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
US$12.75
40.1% undervalued intrinsic discount15 Aug
US$7.64
1Y
-23.0%7D
3.7%